Outbreaks with antibiotic-resistant pathogens are occurring in hospital COVID-19 units, primarily caused by multidrug-resistant organisms that are hard to eradicate from the patient environment, a Centers for Disease Control and Prevention investigator reports.
In a retrospective cohort study, investigators found the addition of a β-lactam antibiotic to daptomycin led to less clinical failure (60-day all-cause mortality and/or 60-day recurrence) in patients with methicillin-resistant Staphylococcus aureus bacteremia.
In a retrospective cohort study, empiric anti-methicillin-resistant Staphylococcus aureus treatment was not associated with a reduction in mortality in any subgroup of patients studied and appeared to cause harm in many.
The key change from the 2009 vancomycin guidelines is the switch from trough-based to area under the curve (AUC)-based dosing and monitoring. This article will highlight key differences between the 2009 and 2020 guidelines, limitations of the new guidelines, and implementation issues.
In a retrospective cohort study, 88,605 patients in the Veterans Administration system who were hospitalized with pneumonia were examined. Thirty-eight percent received empiric anti-methicillin-resistant Staphylococcus aureus (MRSA) treatment. Empiric anti-MRSA treatment was not associated with a reduction in mortality in any subgroup of patients studied and appeared to cause harm in many patients.
In a randomized clinical trial conducted at 27 hospitals in four countries, researchers found that the addition of an antistaphylococcal beta-lactam to vancomycin or daptomycin (99% received vancomycin) did not lead to improved outcomes in MRSA bacteremia. The trial was stopped early because of safety concerns, including a higher risk of acute kidney injury in the combination group.
Using a population-based database, investigators found that the rate of readmission within 30 days following hospitalization for S. aureus bacteremia was high (22%) and resulted in high cost to the healthcare system.